RxDoctor Payments DataLook up a doctor →

David Arkin, MD

Endocrinology, Diabetes & Metabolism · Lawrenceville, GANPI 1891865937

Payments from drug & device makers

$15,124in general payments, 2019–2025

Across 711 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Novo Nordisk$2K
  • Amgen$2K
  • Sanofi-aventis U.S. LLC$1K
  • Lilly USA, LLC$752
  • Insulet Corporation$715
  • plus $7K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott51$1,890
Novo Nordisk102$1,775
Amgen(2 entities)63$1,516
Sanofi-aventis U.S. LLC53$1,259
Lilly USA, LLC46$752
Insulet Corporation35$715
Dexcom, Inc.18$681
AstraZeneca(2 entities)37$596
Tandem Diabetes Care, Inc.12$511
Corcept Therapeutics30$463
Amarin Pharma, Inc.22$350
BETA Bionics, Inc.8$346
Xeris Pharmaceuticals, Inc.17$337
Boehringer Ingelheim19$305
AbbVie22$292
Mannkind Corporation13$276
Radius Health, Inc.13$246
Madrigal Pharmaceuticals4$206
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC12$191
Amneal Pharmaceuticals LLC11$174
Ascensia Diabetes Care US Inc.9$167
Bayer9$143
Ascendis Pharma Endocrinology Inc3$138
Medtronic(2 entities)9$125
Vivus LLC9$124
BD5$111
Astellas Pharma Global Development1$108
Cequr Corporation3$96
IBSA Pharma Inc.6$87
Lifescan, Inc.5$87
Embecta Corp.4$77
Amphastar Pharmaceuticals, Inc.4$73
Novartis3$73
Esperion Therapeutics, Inc.4$72
Shire North American Group Inc5$69
Kyowa Kirin, Inc.3$68
Verity Pharmaceuticals Inc.3$51
Merck4$51
Ipsen Biopharmaceuticals, Inc2$47
Pfizer3$44
Johnson & Johnson3$43
Regeneron Healthcare Solutions, Inc.3$40
Ionis Pharmaceuticals, Inc.2$32
Amryt Pharma Holdings Ltd2$27
Companion Medical, Inc.2$26
Senseonics, Incorporated1$23
Astellas Pharma US Inc1$18
Neurocrine Biosciences, Inc.1$18
Eisai Inc.1$17
Theracosbio, LLC1$17
Recordati_rare_diseases_inc.1$16
Organon1$16
Nevro Corp.1$15
Currax Pharmaceuticals LLC1$15
Nalpropion Pharmaceuticals LLC1$15
Averitas Pharma Inc.1$15
Roche Diabetes Care, Inc.1$14
Silk Road Medical, Inc.1$14
Antares Pharma, Inc.1$14
Acella Pharmaceuticals, LLC1$13

How this compares

$15,124 in reported general payments places this provider in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia

Medicare billing

Part B allowed, 2024
$176,626
Medicare patients
683
Services billed
4,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →